In breast cancer cells, previous studies showed that ErbB2 itself in shape of its p95 carboxy-terminal fragment [24] or via an ErbB2-encoded miRNA downregulate ER expression [21]; so in breast cancer, ErbB2 amplification is suspected to lead to endocrine therapy resistance. This evidence concerns the gene ESR1 and breast carcinoma.